[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"biopsy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:biopsy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,81,107,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100611456","comparison-of-fnb-to-eus-cnb-for-pancreatic-lesions-100611456",false,"NCT07240818","Comparison of FNB to EUS-CNB for Pancreatic Lesions","Tissue Sample Comparison Between 22G FNB Needle and a New EUS Core Needle Biopsy Device for Pancreatic Lesions: A Single Center Prospective Randomized Pilot Trial","Inclusion Criteria:\n\n1. Patients who require EUS and tissue sampling of pancreatic solid lesions (size\\> 2.5 cm)\n2. Patients who can give consent\n\nExclusion Criteria:\n\n1. patients without pancreatic lesions\n2. Pregnant females\n3. Hematologic and Coagulation disorders (platelets \\\u003C 50,000\u002Fmm3, INR \\> 2, ANC \\\u003C1000)\n4. Patients with acute pancreatitis in the immediate 2 weeks before the procedure (if the lesion to be biopsied is in the pancreas)\n5. Cardiorespiratory dysfunction that precludes sedation\n6. patients unable to provide informed consent\n7. Previous chemotherapy or radiotherapy for a pancreatic neoplasm\n8. Patients who are not candidates for emergency surgery in case complications arise from the biopsy","ALL","18 Years","89 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary aim of this study is to compare the tissue specimen quality and diagnostic accuracy of biopsies obtained with one puncture of a regular 22 FNB G needle and the motorized EUS CNB device of pancreatic lesions. The secondary aims are to compare the rate of blood contamination in the specimens obtained from biopsies of pancreatic lesions and the overall procedure duration. The hypothesis of this study is that the proportion of cases in which a single puncture of the lesion in question delivers adequate diagnostic tissue is higher with the motorized EUS CNB than with the 22 G FNB.",[27,28,29],"Diagnosis of a Pancreaticobiliary Disorder","Biopsy","EUS Guided Biopsy",[31,32,33,34],"FNB","EUS-CNB","Endodrill","EUS guided biopsy","NOT_YET_RECRUITING","2026-06-02",{"date":38,"type":39},"2026-06-04","ACTUAL",{"date":41,"type":21},"2026-07-01",{"date":43,"type":21},"2026-11-01",{"name":45,"class":46},"University of California, Davis","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100610726","pioneer-trial-post-transplant-application-of-trugraf-and-trac-molecular-panel-in-renal-transplant-recipients-100610726","NCT07231328","PIONEER Trial (Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients)","Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients","PIONEER","Inclusion Criteria:\n\n* Able to understand the key components of the study as described in the written informed consent document and willing and able to provide written informed consent.\n* At least 18 years of age at the time of screening.\n* Enrollment begins 30 days prior to transplant till day 29 post-transplantation.\n* Recipient of a kidney transplant (either primary or repeat), from either deceased or living donor.\n* Receiving any immunosuppressive regimen.\n* Able and willing to comply with all study procedures, as assessed by the Investigator.\n* Selected by the treating provider to undergo TruGraf and TRAC™ testing as part of routine post-transplant care\n\nExclusion Criteria:\n\nHistory of previous non-kidney solid organ, vascular composite allograft, pancreatic islet, stem cell, or bone marrow transplant.\n\n* History of dual or en-bloc kidney transplants.\n* Recipient or donor with positive test for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis B virus (HBV) nucleic acid testing (NAT), hepatitis C virus (HCV) antibody, HCV NAT, human immunodeficiency virus (HIV), or HIV NAT.\n* Patients known to be pregnant or with plans to become pregnant over the 24 months after enrollment.\n* History or presence of coagulopathy, thrombophilia, unexplained bleeding or clotting disorders, or use of or documented plans for use of systemic anticoagulants at the time of screening, with the exception of uremic coagulopathy or prophylactic heparin preparations.\n* History or presence, upon clinical evaluation, of any illness or condition that, in the opinion of the Investigator, would interfere with the ability to provide informed consent or comply with study instructions",{"count":57,"type":21},600,"OBSERVATIONAL","This is an observational, prospective, multi-center trial designed to evaluate clinical outcomes in kidney transplant recipients undergoing TruGraf and TRAC monitoring.\n\nApproximately 15 U.S. sites",[61,62,63,28,64],"Immunosuppression Management","Biomarkers \u002F Blood","Subclinical Rejection","Kidney Transplant Rejection",[66,67,68,69,70],"TRAC-ID ASSAY","Kidney Transplant rejection","TruGraf, TRAC\u002FTRAC ID biomarker panel","TruGraf","TRAC","2025-11-13",{"date":73,"type":39},"2025-11-17",{"date":75,"type":21},"2025-11-20",{"date":77,"type":21},"2029-03-31",{"name":79,"class":80},"Transplant Genomics, Inc.","INDUSTRY",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":47},"100424601","comparation-of-endoscopic-biopsy-and-postoperative-specimen-for-the-molecular-diagnosis-of-gastric-cancer-100424601","NCT04809025","Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer","EBPS","Inclusion Criteria:\n\n1. Lower age limit of research subjects 18 years old and upper age limit of 75 years old.\n2. Histologically proven primary gastric adenocarcinoma (Diagnostic biopsies must be collected within 12 months prior to enrollment).\n3. Written informed consent from the patient.\n4. Patients planned for radical R0 gastrectomy.\n\nExclusion Criteria:\n\n1. Female in pregnancy or lactation.\n2. Patients with gastric cancer who can not undergo tumor resection\n3. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases.\n4. Patients with poor compliance or considered to be poor compliance.\n5. Patients received any anticancer drugs, biotherapy, radiotherapy or immunotherapy within 4 weeks before or after enrollment.\n6. Patients after organ transplantation, long-term need to take immunosuppressants, autoimmune diseases.","75 Years",{"count":90,"type":21},510,"This study aims to test the hypothesis that the diagnosis for histological type, histological grade, LAUREN type, HER-2 expression, MSI\u002FdMMR status, and EBV status in gastric cancer is at least as reliable when performed on endoscopic biopsy specimens as on surgical resection specimens.",[93,94,28,95],"Stomach Neoplasms","Endoscopy","Pathology",[93,94,28,95],"RECRUITING","2025-09-24",{"date":100,"type":39},"2025-09-29",{"date":102,"type":39},"2021-05-24",{"date":104,"type":21},"2026-09-01",{"name":106,"class":46},"Fudan University",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":115,"minAge":116,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":22,"phases":119,"briefSummary":120,"conditions":121,"keywords":126,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":47},"100601760","molecular-breast-imaging-mbi-guided-biopsy-100601760","NCT07114679","Molecular Breast Imaging (MBI)-Guided Biopsy","Molecular Breast Imaging (MBI)-Guided Biopsy Pilot SBIR","MBI-GB-Pilot","Inclusion Criteria:\n\n* dense breasts (BI-RADS C or D) on screening DBT\n\nExclusion Criteria:\n\n* pregnancy","FEMALE","21 Years",{"count":118,"type":21},250,[24],"The goal of this pilot clinical trial is to demonstrate supplemental screening MBI (molecular breast imaging) in women with dense breasts. The main questions it aims to answer are:\n\n* Does screening MBI find more cancer than screening DBT (3D mammography, digital breast tomosynthesis?\n* Does screening MBI result in more call-backs for biopsy than DBT?\n* How well does MBI-guided biopsy conform with pathology reports?\n\nResearchers will compare screening MBI to screening DBT to see if MBI is more sensitive to detecting cancer in women with dense breasts.\n\nParticipants will\n\n* Receive both screening DBT and screening MBI\n* Receive either DBT-guided or MBI-guided biopsy (randomly assigned), if required by the screening images",[122,123,124,28,125],"Breast Cancer Detection","Breast Neoplasm","Molecular Imaging","Dense Breasts",[127,128,129,130,131,132,133,134,135],"screening","crossover","single-group","pilot","biopsy","randomized assignment","dense breasts","MBI","molecular imaging","2025-08-03",{"date":138,"type":39},"2025-08-11",{"date":140,"type":21},"2027-06",{"date":142,"type":21},"2028-06",{"name":144,"class":80},"Smart Breast Corp.",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":47},"100591590","zeroheart-biopsy---prediction-of-deceased-donor-heart-transplant-performance-from-organ-donors-using-pre-transplant-biopsies---a-pilot-study-100591590","NCT06982404","ZeroHeart Biopsy - Prediction of Deceased Donor Heart Transplant Performance From Organ Donors Using Pre-Transplant Biopsies - A Pilot Study","ZeroHeart","Inclusion Criteria:\n\nAll hearts from standard and expanded criteria donors as well as donor hearts from Donation after circulatory death (DCD) undergoing a heart biopsy at pre-implantation (at procurement) will be included. Consent will be obtained from the recipient at the time of transplant listing.\n\nExclusion Criteria:\n\nHearts will be excluded from the study if the participating clinician decides to discard the organ before transplantation or the recipient declines that the biopsy will be performed at the organ procurement.",{"count":153,"type":21},50,"The goal of this observational study is to evaluate whether molecular analysis of donor heart biopsies taken at the time of organ removal (\"Time Zero\") can help predict the future function and rejection risk of the transplanted heart in adult transplant recipients.\n\nThe main questions it aims to answer are:\n\n* Can early molecular injury in the donor heart, caused by brain death or circulatory death, be detected at the time of organ removal?\n* Can these early molecular findings predict short-, mid-, and long-term transplant outcomes, such as graft function or rejection?\n\nParticipants will:\n\n* Include heart donors whose hearts are being transplanted (both standard and marginal donors, including DBD and DCD cases)\n* Provide two small biopsies from the donor heart at the time of organ removal: one for routine pathology, one for microarray-based molecular analysis\n* Have routine follow-up biopsies after transplantation as part of standard care (no additional procedures required beyond medical standard)\n\nResearchers will compare biopsy results from different donor types (standard vs. marginal, DBD vs. DCD) to see if early molecular signals are linked to later heart transplant outcomes.",[156,157,158,159,28,160],"Heart Transplantation","Graft Rejection","Myocardial Injury","Organ Preservation","Gene Expression Profiling","2025-05-13",{"date":163,"type":39},"2025-05-21",{"date":165,"type":39},"2025-05-12",{"date":167,"type":21},"2028-05-31",{"name":169,"class":46},"Medical University of Vienna"]